Boehringer Will Test How Pradaxa Stacks Up To The Competition In Real-World Study
This article was originally published in The Pink Sheet Daily
Global observational study is assessing real-world experience with Pradaxa and other anticoagulants in patients with newly diagnosed atrial fibrillation and at risk of stroke. Results are due in 2020.
You may also be interested in...
A new Lancet meta-analysis suggests that while four new anticoagulants are more effective than warfarin, there is little differentiation among the products. Pressed to compare the drugs at AHA, experts were apt to highlight similarities and call for competitive pricing and head-to-head trials.
Update of label not based on new post-NDA or post-marketing data, but on a fuller review of pivotal trial data and discussions between Boehringer Ingelheim and FDA.
Though other novel anticoagulants are in development for treatment and prevention of venous thromboembolism, Janssen and its partner Bayer are hoping Xarelto will be coming out ahead.